Filing Details

Accession Number:
0001104659-15-067089
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-09-24 21:26:28
Reporting Period:
2015-09-23
Filing Date:
2015-09-24
Accepted Time:
2015-09-24 21:26:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1436304 Kythera Biopharmaceuticals Inc KYTH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559510 Keith Klein C/O Kythera Biopharmaceuticals, Inc.
30930 Russell Ranch Road, 3Rd Floor
Westlake Village CA 91362
General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-09-23 14,203 $8.22 18,271 No 4 M Direct
Common Stock Disposition 2015-09-23 14,203 $74.90 4,068 No 4 S Direct
Common Stock Acquisiton 2015-09-23 26,800 $27.50 30,848 No 4 M Direct
Common Stock Disposition 2015-09-23 26,800 $74.90 4,068 No 4 S Direct
Common Stock Acquisiton 2015-09-23 11,150 $44.02 15,198 No 4 M Direct
Common Stock Disposition 2015-09-23 11,150 $74.90 4,068 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Disposition 2015-09-23 14,203 $0.00 14,203 $8.22
Common Stock Stock Options Disposition 2015-09-23 13,400 $0.00 13,400 $27.50
Common Stock Stock Options Disposition 2015-09-23 13,400 $0.00 13,400 $27.50
Common Stock Stock Options Disposition 2015-09-23 11,150 $0.00 11,150 $44.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-02-01 No 4 M Direct
0 2023-01-29 No 4 M Direct
6,700 2023-01-29 No 4 M Direct
15,608 2024-01-22 No 4 M Direct
Footnotes
  1. The shares subject to these options vested 100% upon the achievement of certain performance milestones approved by the Issuer's Board of Directors.
  2. 25% of the shares subject to the option vested on the first anniversary measured from January 1, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.